This site is intended for health professionals only

Published on 24 March 2010

Share this story:

Brain scare stops Stimuvax trials


Trials of the cancer drug Stimuvax have been temporarily suspended because of safety concerns, biotechnology company Oncothyreon has announced.

The company said its partner Merck Serono had imposed the moratorium after a “suspected unexpected serious adverse reaction” in a patient, specifically inflammation of the brain.

Stimuvax is Oncothyreon’s lead drug candidate. The company currently has no products on the market.

Officials said a larger trial of the treatment, one focused on breast and lung cancer, had also been suspended.

Merck Serono is part of Germany pharmaceutical giant Merck.

Copyright Press Association 2010

Merck Sereno



Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine